January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Amid growing concern of the overuse and misuse of obesity drugs, the UK’s pharmacies regulator rolled out stricter guidelines ...

Robert F. Kennedy Jr.’s HHS nomination moves to a full Senate vote; Donald Trump’s tariff war sparks China-related concerns for biopharma; Pfizer, Merck and more announce Q4 and 2024 earnings; and the ...

The week's investing action plan includes a strong dose of pharma and biotech earnings, January econ reports, plus Amazon and ...

The S&P 500 index trades at a forward price/earnings ratio of 21.9. The U.S. large-cap benchmark stock index is weighted by market capitalization. The index's current forward P/E valuation is 18% ...

Vijay Pande, PhD, founding investor of Andreessen Horowitz's Bio + Health fund and a general partner with the tech venture capital firm , discusses how AI’s uptake in healthcare will shape its ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

Wednesday closed up +0.39%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.71%, and the Nasdaq 100 Index ($IUXX) ...

Aktis Oncology, an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / February 5, 2025 / Lexaria Bioscience Corp. (the "Company" or " ...